Skin care composition with synergistic repair anti-aging efficacy and use thereof

Abstract

The present application relates to a kind of skin care compositions with synergistic repair anti-aging efficacy and its application, belong to the field of cosmetics.The skin care compositions with synergistic repair anti-aging efficacy of the present application include the following components: L-arginine, L-hydroxyproline, L-valine, yeast polypeptide, PDRN from spilanthes acmella, PDRN from edelweiss, leukocyte extract.The skin care compositions with synergistic repair anti-aging efficacy of the present application have significant repair, anti-aging efficacy.

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, and in particular to a skin care composition with synergistic repair and anti-aging effects and its application. Background Technology

[0002] Skin aging is a complex biological process involving the molecular, cellular, and tissue levels. Its characteristics include, but are not limited to, the degradation and reduced synthesis of the dermal extracellular matrix (especially type I and type III collagen), disruption of the elastic fiber network, decline in fibroblast proliferation and regeneration, impaired skin barrier function, and accompanying chronic low-grade inflammation. Currently, the development of active cosmetic ingredients targeting skin aging often focuses on single pathways, such as supplementing collagen synthesis precursors (e.g., specific amino acids or peptides), providing exogenous antioxidants to combat photoaging, or adding cell growth factors to promote tissue repair. However, the skin, as a highly coordinated system, relies on the precise collaboration and positive feedback of multiple pathways for repair and regeneration. Single-component strategies often have limited effectiveness due to limited target sites, poor transdermal efficiency, or lack of support from other pathways.

[0003] Specifically, amino acids and peptides, as direct raw materials for protein synthesis, are the cornerstone of collagen metabolism; however, their bioavailability and synthesis-promoting efficiency when used alone need improvement. Polydeoxyribonucleotides (PDRNs), as bioactive substances, have been shown to promote DNA repair, cell proliferation, and angiogenesis through pathways such as activating adenosine A2A receptors, demonstrating potential in tissue repair. However, PDRNs from different plant sources may have different emphases in anti-inflammatory and antioxidant auxiliary effects due to variations in their accompanying secondary metabolites. A single PDRN source or an unoptimized compound ratio may not be able to comprehensively address the multiple stresses in aging skin. Leukocyte extracts are rich in various growth factors, cytokines, and exosomes, which can mimic in vivo repair signals and regulate the immune microenvironment; however, their full efficacy depends on the target cells being in a good nutritional and metabolic state.

[0004] Current technologies attempt to simply physically mix the aforementioned components, but this "crude" formulation lacks in-depth research into whether specific compatibility exists between the sub-components, particularly between PDRN from different sources, and between amino acid / peptide complexes and PDRN and biological extracts, and whether synergistic effects beyond the simple sum of the components can be generated. This lack of synergy makes it difficult for the final product to achieve a complete, highly effective anti-aging repair process, encompassing cellular nutrition supply, DNA damage repair, and tissue microenvironment remodeling. Therefore, there is an urgent need in this field for a scientifically designed and validated synergistic composition that integrates multiple anti-aging pathways, including nutritional support, cell activation, DNA repair, and microenvironment regulation, to overcome the shortcomings of existing technologies and provide a skin repair and anti-aging solution with significant effects and a clearly defined mechanism. Summary of the Invention

[0005] The purpose of this invention is to overcome the shortcomings of the prior art and provide a skin care composition with synergistic repair and anti-aging effects and its application.

[0006] To achieve the above objectives, the technical solution adopted by the present invention is as follows: In a first aspect, the present invention provides a skin care composition with synergistic repair and anti-aging effects, comprising the following components: L-arginine, L-hydroxyproline, L-valine, yeast polypeptide, PDRN from purslane, PDRN from edelweiss, and leukocyte extract; The mass ratio of PDRN derived from purslane to PDRN derived from edelweiss is 1:(0.1-1).

[0007] Preferably, the skin care composition comprises the following components in parts by weight: L-Arginine: 0.5-1.5 parts; L-Hydroxyproline: 1.0-3.0 parts; L-valine: 0.5-1.5 parts; Yeast polypeptides: 1.0-3.0 parts; PDRN from purslane: 1.0-3.0 parts; PDRN from Edelweiss: 0.5-1.5 parts; Leukocyte extract: 0.5-2.0 parts.

[0008] More preferably, the skin care composition comprises the following components in parts by weight: L-arginine: 1.0 part; L-hydroxyproline: 2.0 parts; L-valine: 1.0 part; Yeast polypeptide: 2.0 parts; PDRN from purslane: 2.0 copies; PDRN from Edelweiss: 1.0 copy; Leukocyte extract: 1.0 part.

[0009] The present invention provides a composition by selecting a specific mass ratio of L-arginine, L-hydroxyproline, L-valine, yeast polypeptide, PDRN from purslane, PDRN from edelweiss, and leukocyte extract. This composition can significantly increase the proliferation rate of in vitro fibroblasts and promote the secretion of type I collagen. In addition, the composition also has certain antioxidant and repair effects.

[0010] In a second aspect, the present invention provides the use of the skin care composition as described in the first aspect in the preparation of cosmetics for repairing the skin barrier.

[0011] Thirdly, the present invention provides the use of the skin care composition as described in the first aspect in the preparation of cosmetics for promoting collagen synthesis, anti-wrinkle, and anti-aging.

[0012] Fourthly, the present invention provides a cosmetic with repairing and anti-aging effects, wherein the cosmetic includes the skin care composition as described in the first aspect.

[0013] Preferably, the cosmetic also includes excipients acceptable in the cosmetic field, the excipients being selected from one or more of moisturizers, emulsifiers, thickeners, preservatives, pH adjusters, and solvents.

[0014] Preferably, the moisturizer is one or more of glycerin, sodium hyaluronate, and 1,3-butanediol.

[0015] Preferably, the solvent is deionized water and / or oil.

[0016] Compared with the prior art, the beneficial effects of the present invention are as follows: This invention scientifically combines L-arginine, L-hydroxyproline, L-valine, yeast polypeptides, PDRN derived from purslane, PDRN derived from edelweiss, and leukocyte extract in specific proportions to create a novel, multi-target synergistic skin repair and anti-aging solution. The core beneficial effect of this composition lies in the significant synergistic effect between its various active components, rather than a simple additive effect. Specifically, the synergistic effect is manifested in the following ways: L-arginine, L-hydroxyproline, L-valine, and yeast polypeptides provide skin cells with key nutrient substrates and metabolic activation signals necessary for the synthesis of collagen and structural proteins, laying the material and energy foundation for biosynthesis; the specific proportions of PDRN derived from purslane and PDRN derived from edelweiss integrate their respective advantages in promoting DNA repair, cell regeneration, and anti-inflammatory and antioxidant properties, forming a composite repair module targeting cell damage and stress; and the leukocyte extract introduces a complex bioactive signaling network, effectively regulating the skin's immune microenvironment and providing key growth factor stimulation for cell proliferation and tissue remodeling.

[0017] The synergistic mechanism of the above three components lies in the positive and mutually reinforcing functional cycle they form: the nutrient substrates provided by amino acid peptides ensure that cells have sufficient "building materials" to respond when they receive proliferation and synthesis signals from PDRN and leukocyte extract; PDRN's DNA repair function and enhancement of cell vitality optimize the functional state of cells, enabling them to utilize nutrients more efficiently and respond to growth factor signals; the regulation of the microenvironment by leukocyte extract creates a low-inflammatory, high-activity state conducive to repair, and its released signaling molecules can further interact with the active pathway of PDRN, amplifying the repair-promoting effect. This three-in-one synergistic mechanism of "nutrient supply-damage repair-signal regulation" allows the composition of this invention to simultaneously intervene in key aspects of skin aging at multiple levels from molecules and cells to the tissue microenvironment, thereby achieving comprehensive, efficient, and lasting skin barrier repair, collagen promotion, anti-wrinkle, and anti-aging effects, solving the technical problems of limited effectiveness and efficiency of single-component or ordinary compound products. Detailed Implementation

[0018] To better understand the present invention, the present invention will be further described below with reference to specific embodiments. The terminology used in the embodiments is for describing specific implementation schemes and does not constitute a limitation on the scope of protection of the present invention.

[0019] Unless otherwise specified, experimental methods in the following examples are generally performed under standard conditions or as recommended by the manufacturer. Unless otherwise stated, all measurements are by weight in percentages and parts.

[0020] Some of the raw materials and their sources are as follows: L-Arginine: Purchased from Suzhou Youyi Biotechnology Co., Ltd. L-Hydroxyproline: Purchased from Suzhou Youyi Biotechnology Co., Ltd. L-Valine: Purchased from Suzhou Youyi Biotechnology Co., Ltd. Yeast polypeptide: purchased from Guangzhou Xinkai Chemical Technology Co., Ltd.; PDRN from purslane: purchased from Zhongzhi (Shandong) Biotechnology Co., Ltd.; PDRN from Edelweiss: purchased from Zhongzhi (Shandong) Biotechnology Co., Ltd.; PDRN-1: Purchased from Regemin Biotechnology, extracted from the testes of male salmon; Leukocyte extract: purchased from Baihong Synthetic Biotechnology (Yantai) Co., Ltd.; Unless otherwise specified, the reagents, methods and equipment used in this invention are all conventional reagents, methods and equipment in the field; and unless otherwise specified, the raw materials used in parallel experiments are from the same batch.

[0021] Preparation of skin care compositions with synergistic repair and anti-aging effects Composition 1 Composed of the following components by mass: L-arginine: 1.0 part; L-hydroxyproline: 2.0 parts; L-valine: 1.0 part; Yeast polypeptide: 2.0 parts; PDRN from purslane: 2.0 copies; PDRN from Edelweiss: 1.0 copy; Leukocyte extract: 1.0 part; Preparation method: Mix the above raw materials evenly to obtain the composition.

[0022] Composition 2 Composed of the following components by mass: L-arginine: 0.1 parts; L-hydroxyproline: 1.0 part; L-valine: 0.5 parts; Yeast polypeptide: 1.0 part; PDRN from purslane: 1.0 copy; PDRN from Edelweiss: 0.3 parts; Leukocyte extract: 0.5 parts; The preparation method is the same as that of composition 1.

[0023] Composition 3 Composed of the following components by mass: L-arginine: 0.5 parts; L-hydroxyproline: 3.0 parts; L-valine: 1.0 part; Yeast polypeptide: 3.0 parts; PDRN from purslane: 3.0 copies; PDRN from Edelweiss: 1.5 copies; Leukocyte extract: 2.0 parts; The preparation method is the same as that of composition 1.

[0024] Composition 4 Composed of the following components by mass: L-arginine: 1.0 part; L-hydroxyproline: 2.0 parts; L-valine: 1.0 part; Yeast polypeptide: 2.0 parts; PDRN from purslane: 3.0 copies; PDRN from Edelweiss: 0.3 parts; Leukocyte extract: 1.0 part; The preparation method is the same as that of composition 1.

[0025] Composition 5 Composed of the following components by mass: L-arginine: 1.0 part; L-hydroxyproline: 2.0 parts; L-valine: 1.0 part; Yeast polypeptide: 2.0 parts; PDRN from purslane: 1.5 copies; PDRN from Edelweiss: 1.5 copies; Leukocyte extract: 1.0 part; The preparation method is the same as that of composition 1.

[0026] Composition ① Unlike composition 1, it lacks L-arginine. The missing mass fraction is made up by L-hydroxyproline, L-valine, and yeast polypeptide in a mass ratio of 2:1:2. The remaining components, mass fractions of the components, and preparation methods are the same as those of composition 1.

[0027] Composition ② Unlike composition 1, it lacks L-hydroxyproline. The missing mass fraction is made up by L-arginine, L-valine and yeast polypeptide in a mass ratio of 1:1:2. The remaining components, mass fractions of the components and preparation methods are the same as those of composition 1.

[0028] Composition ③ Unlike composition 1, it lacks L-valine. The missing mass fraction is made up by L-arginine, L-hydroxyproline and yeast polypeptide in a mass ratio of 1:2:2. The remaining components, mass fractions of the components and preparation methods are the same as those of composition 1.

[0029] Composition ④ Unlike composition 1, this composition lacks yeast polypeptides. The missing mass fractions are made up by L-arginine, L-hydroxyproline, and L-valine in a mass ratio of 1:2:1. The remaining components, their mass fractions, and preparation methods are the same as those in composition 1.

[0030] Composition ⑤ Unlike composition 1, it lacks PDRN from purslane, and the missing mass fraction is made up with PDRN from edelweiss. The remaining components, mass fractions of components, and preparation methods are the same as those of composition 1.

[0031] Composition ⑥ Unlike composition 1, it lacks PDRN from Edelweiss, and the missing mass fraction is made up with PDRN from Portulaca oleracea. The remaining components, mass fractions of components, and preparation methods are the same as those of composition 1.

[0032] Composition ⑦ Unlike composition 1, it lacks L-arginine, L-hydroxyproline, L-valine, and yeast polypeptide. The missing mass fractions are made up by PDRN from purslane and PDRN from edelweiss in a mass ratio of 2:1. The remaining components, mass fractions of components, and preparation methods are the same as those of composition 1.

[0033] Composition ⑧ Unlike composition 1, it lacks PDRN from purslane and PDRN from edelweiss. The missing mass fractions are made up with L-arginine, L-hydroxyproline, L-valine and yeast polypeptide in a mass ratio of 1:2:1:2. The remaining components, mass fractions of components and preparation methods are the same as those of composition 1.

[0034] Composition 9 Unlike composition 1, it lacks PDRN from purslane and PDRN from edelweiss. The missing mass fractions are made up with PDRN-1. The remaining components, mass fractions of components, and preparation methods are the same as those of composition 1.

[0035] Composition ⑩ Unlike composition 1, this composition lacks leukocyte extract. The missing mass fractions are made up by L-arginine, L-hydroxyproline, L-valine, yeast polypeptide, PDRN from purslane, and PDRN from edelweiss in a mass ratio of 1:2:1:2:2:1. The remaining components, mass fractions, and preparation methods are the same as in composition 1.

[0036] Composition A Unlike Composition 1, it lacks L-arginine, L-hydroxyproline, L-valine, yeast polypeptide, PDRN from purslane, and PDRN from edelweiss. The missing mass fractions are made up by leukocyte extract. The remaining components, mass fractions of components, and preparation methods are the same as those of Composition 1.

[0037] Composition B Composed of the following components by mass: L-arginine: 1.0 part; L-hydroxyproline: 2.0 parts; L-valine: 1.0 part; Yeast polypeptide: 2.0 parts; PDRN from purslane: 1.0 copy; PDRN from Edelweiss: 2.0 copies; Leukocyte extract: 1.0 part; The preparation method is the same as that of composition 1.

[0038] Composition C Composed of the following components by mass: L-arginine: 2.0 parts; L-hydroxyproline: 0.5 parts; L-valine: 2.0 parts; Yeast polypeptide: 0.5 parts; PDRN from purslane: 2.0 copies; PDRN from Edelweiss: 1.0 copy; Leukocyte extract: 1.0 part; The preparation method is the same as that of composition 1.

[0039] Preparation of serums with repairing and anti-aging effects Serum 1 Composed of the following components by mass percentage: Composition 1: 3wt% Glycerin: 3wt% Deionized water to 100 wt%; Preparation method: Mix the composition, glycerin, and deionized water evenly to obtain the essence.

[0040] Serum 2 Unlike serum 1, composition 2 is used to replace composition 1 by the same mass percentage, while the remaining components, component mass percentages, and preparation methods are the same as those for serum 1.

[0041] Serum 3 Unlike serum 1, composition 3 is used to replace composition 1 by the same mass percentage, while the remaining components, component mass percentages, and preparation methods are the same as those for serum 1.

[0042] Serum 4 Unlike serum 1, composition 4 is used to replace composition 1 by the same mass percentage, while the remaining components, component mass percentages, and preparation methods are the same as those for serum 1.

[0043] Serum 5 Unlike serum 1, composition 5 is used to replace composition 1 by the same mass percentage, while the remaining components, component mass percentages, and preparation methods are the same as those in serum 1.

[0044] Serum 6 Composed of the following components by mass percentage: Composition 1: 0.5 wt% Glycerin: 3wt% Deionized water to 100 wt%; The preparation method is the same as that of essence 1.

[0045] Serum 7 Composed of the following components by mass percentage: Composition 1: 5wt% Glycerin: 3wt% Deionized water to 100 wt%; The preparation method is the same as that of essence 1.

[0046] Serum ① Unlike serum 1, composition 1 is replaced by composition ① at the same mass percentage, while the remaining components, component mass percentages, and preparation methods are the same as those in serum 1.

[0047] Serum ② Unlike serum 1, composition 2 is used to replace composition 1 by the same mass percentage, while the remaining components, component mass percentages, and preparation methods are the same as those for serum 1.

[0048] Serum ③ Unlike serum 1, composition 3 is used to replace composition 1 by the same mass percentage, while the remaining components, component mass percentages, and preparation methods are the same as those for serum 1.

[0049] Essence ④ Unlike serum 1, composition 4 is used to replace composition 1 by the same mass percentage, while the remaining components, component mass percentages, and preparation methods are the same as those for serum 1.

[0050] Essence ⑤ Unlike serum 1, composition 5 is used to replace composition 1 by the same mass percentage, while the remaining components, component mass percentages, and preparation methods are the same as those in serum 1.

[0051] Essence ⑥ Unlike serum 1, composition 6 is used to replace composition 1 by the same mass percentage, while the remaining components, component mass percentages, and preparation methods are the same as those for serum 1.

[0052] Essence ⑦ Unlike serum 1, composition 7 is used to replace composition 1 by the same mass percentage, while the remaining components, component mass percentages, and preparation methods are the same as those for serum 1.

[0053] Serum ⑧ Unlike serum 1, composition ⑧ is used to replace composition 1 by the same mass percentage, while the remaining components, component mass percentages, and preparation methods are the same as those for serum 1.

[0054] Serum 9 Unlike serum 1, composition 9 is used to replace composition 1 by the same mass percentage, while the remaining components, component mass percentages, and preparation methods are the same as those for serum 1.

[0055] Serum 10 Unlike serum 1, composition 1 is replaced by composition ⑩ at the same mass percentage, while the remaining components, component mass percentages, and preparation methods are the same as those in serum 1.

[0056] Serum A Unlike serum 1, composition A is used to replace composition 1 by the same mass percentage, while the remaining components, component mass percentages, and preparation methods are the same as those in serum 1.

[0057] Serum B Unlike serum 1, composition B is used to replace composition 1 by a certain percentage by mass, while the remaining components, component mass percentages, and preparation methods are the same as those for serum 1.

[0058] Serum C Unlike serum 1, composition 1 is replaced by composition C at the same mass percentage, while the remaining components, component mass percentages, and preparation methods are the same as those in serum 1.

[0059] Blank Essence Composed of the following components by mass percentage: Glycerin: 3wt% Deionized water to 100 wt%; Preparation method: Mix glycerin and deionized water evenly to obtain the essence.

[0060] Efficacy verification Test Example 1: Effect of the composition on fibroblast proliferation Cells: Human dermal fibroblasts (HDF, passages 5-8); Test samples: Compositions 1-5, Compositions ①-⑩, and Composition AC, with a concentration of 1 mg / mL, in DMEM complete culture medium; Blank sample: DMEM complete culture medium; Experimental steps: 1. Digest and count HDF cells, seed them in 96-well plates at a density of 5 × 10^3 cells per well, with a volume of 100 μL per well, and incubate at 37°C in a 5% CO2 incubator for 24 hours to allow the cells to adhere.

[0061] 2. Discard the old culture medium and add 100 μL of test sample to each well. Each group has 6 replicates.

[0062] 3. Continue training for another 72 hours.

[0063] 4. Four hours before the end of the incubation, add 10 μL of LCK-8 reagent to each well.

[0064] 5. After incubation for another 4 hours, measure the absorbance (OD value) of each well using a microplate reader at a wavelength of 450 nm.

[0065] 6. Data Processing: Calculate the average OD value of each group's 6 replicates. Cell proliferation rate (%) = (OD value of experimental group - OD value of control group) / OD value of control group × 100% + 100%. The proliferation rate of the control group is counted as 100%.

[0066] The results are shown in Table 1.

[0067] Table 1 Effects of the composition on fibroblast proliferation Group Cell proliferation rate (%) Composition 1 85.4 Composition 2 80.1 Composition 3 81.9 Composition 4 77.5 Composition 5 79.3 Composition ① 64.6 Composition ② 62.1 Composition ③ 66.9 Composition ④ 65.1 Composition ⑤ 68.1 Composition ⑥ 66.2 Composition ⑦ 58.2 Composition ⑧ 73.4 Composition 9 58.5 Composition ⑩ 63.4 Composition A 55.2 Composition B 62.8 Composition C 56.9 As shown in Table 1, the sample using the core formulation of this invention (Composition 1) exhibited the highest cell proliferation-promoting effect. Any comparative composition lacking a single active component (Composition ① lacking L-arginine, Composition ② lacking L-hydroxyproline, Composition ③ lacking L-valine, Composition ④ lacking yeast polypeptide, Composition ⑤ lacking PDRN from purslane, Composition ⑥ lacking PDRN from edelweiss, Composition ⑩ lacking leukocyte extract) showed a significant and consistent decrease in its proliferation-promoting ability, demonstrating that all seven components are indispensable for achieving the optimal proliferation-promoting effect. Compositions with altered internal mass ratios, including Compositions 4, 5, and B (with altered ratios of the two PDRNs), and Composition C (with altered amino acid / peptide ratios), also showed significantly lower effects than Composition 1, indicating that the specific mass ratio is key to achieving a synergistic effect. Of particular importance, the proliferation-promoting effect of samples completely lacking the amino acid / peptide component (composition ⑦) or completely lacking the PDRN component (composition ⑧) was severely limited. This confirms from both positive and negative perspectives that "nutritional and metabolic support" and "repair and activation signals" must coexist and synergistically drive the optimal cell proliferation response. Furthermore, samples using PDRN from non-specific sources (composition ⑨) or retaining only leukocyte extract (composition A) showed the weakest effects, further highlighting the specific value of PDRN formulations from specific plant sources and the fundamental supporting role of other components. In summary, L-arginine, L-hydroxyproline, L-valine, and yeast peptides provide the synthetic precursors and metabolic driving forces required for cell proliferation; PDRN from purslane and edelweiss synergistically transmits repair signals that promote DNA synthesis and cell cycle progression; and leukocyte extract optimizes the proliferation microenvironment and provides growth factor stimulation. These three types of components are tightly coupled in the ratios described in this invention, forming a highly efficient synergistic network, thereby achieving cell proliferation effects that surpass any individual combination or non-optimal ratio.

[0068] Test Example 2: Effect of the composition on type I collagen secretion by HDF cells Cells: Human dermal fibroblasts (HDF, passages 5-8); Test samples: Compositions 1-5, Compositions ①-⑩, and Composition AC, with a concentration of 1 mg / mL, in DMEM complete culture medium; Blank sample: DMEM complete culture medium; Experimental steps: A1: HDF cells were seeded at a density of 2×10^5 / well in 12-well plates and cultured for 24 hours to adhere to the plate.

[0069] A2: Discard the old culture medium, replace it with the test sample, and continue culturing for 48 hours. Each group has 4 replicates.

[0070] A3: Collect the cell supernatant and centrifuge at 4°C and 3000 rpm for 10 minutes to remove cell debris.

[0071] The concentration of type I collagen in each experimental group was measured strictly according to the instructions of the human type I collagen (COL1A1) ELISA kit, and then the enhancement rate of type I collagen secretion by the composition was calculated. Increase rate / % = (Concentration of type I collagen in test sample - Concentration of type I collagen in blank sample) / Concentration of type I collagen in blank sample × 100% Table 2. Effects of the composition on the secretion of type I collagen by fibroblasts. Group Type I collagen synthesis enhancement rate (%) Composition 1 68.3 Composition 2 63.6 Composition 3 66.7 Composition 4 61.4 Composition 5 60.8 Composition ① 50.1 Composition ② 46.2 Composition ③ 52.3 Composition ④ 49.7 Composition ⑤ 53.9 Composition ⑥ 51.2 Composition ⑦ 39.7 Composition ⑧ 52.8 Composition 9 41.3 Composition ⑩ 48.5 Composition A 15.8 Composition B 47.9 Composition C 40.5 The results clearly showed that composition 1 had the most significant effect on enhancing collagen synthesis. The collagen-promoting effects of all comparative samples were inferior to those of composition 1. Specifically, the absence of any amino acid or yeast polypeptide (compositions ①-④) led to a decrease in the collagen synthesis enhancement rate, with the absence of L-hydroxyproline (composition ②), a characteristic amino acid of collagen, having a particularly significant impact. This directly confirms the necessity of specific amino acids as key "raw materials" for collagen biosynthesis. The absence of any PDRN (compositions ⑤, ⑥) or all PDRN (composition ⑧), or the use of ordinary PDRN as a substitute (composition ⑨), all weakened the collagen-promoting effect, indicating that PDRN from purslane and edelweiss has a unique advantage in synergistically upregulating collagen gene expression. The absence of leukocyte extract (composition ⑩) resulted in a reduced effect, suggesting that the cytokine signals it provides (such as TGF-β) play a crucial role in activating the fibroblast synthetic phenotype. When the amino acid / peptide base is completely lacking (composition ⑦), the collagen-promoting effect decreases sharply, and the effect is weakest when only leukocyte extract is present (composition A). This extreme case demonstrates that the lack of synthetic substrates or the lack of core repair and induction signals cannot effectively drive collagen biosynthesis. Changing the internal ratio of PDRN (compositions 4, 5, and B) or the internal ratio of amino acids (composition C) also leads to a decline in effect, confirming that the specific mass ratio is crucial for optimizing the synergistic pathway of "raw material supply-gene activation-signal induction". Therefore, the compositions of the present invention provide sufficient synthetic raw materials and metabolic support through a specific ratio of amino acids / peptides, synergistically promote collagen gene transcription and reduce inflammatory degradation through a specific combination of dual plant PDRNs, and provide key synthetic phenotypic transformation signals through leukocyte extract. The convergence and synergistic amplification of multiple pathways ultimately achieve highly efficient promotion of type I collagen synthesis.

[0072] Experiment 3: Determination of the antioxidant capacity of the composition Experiment 3-1: Determination of the antioxidant efficacy of the composition Test samples: Compositions 1-5, ①-⑩, and Composition AC with a concentration of 1 mg / mL, and anhydrous ethanol as the solvent.

[0073] Experimental steps: Mix 100 μL of the test sample with 100 μL of 0.1 mM DPPH ethanol solution in a 96-well plate, and react at room temperature in the dark for 30 minutes. Measure the absorbance (As) at 517 nm using a microplate reader. Simultaneously, measure the absorbance (Ac) of 100 μL ethanol and 100 μL DPPH solution, and the absorbance (Ab) of 100 μL sample and 100 μL ethanol.

[0074] Clearance rate (%) = [1 - (As - Ab) / Ac] × 100% Experiment 3-2: Effect of the composition on protection against hydrogen peroxide-induced cellular oxidative damage Cells: Human dermal fibroblasts (HDF, passages 5-8); Test samples: Compositions 1-5, ①-⑩, and Composition AC with a concentration of 1 mg / mL, in DMEM complete culture medium; Blank sample: DMEM complete culture medium; HDF cells were seeded in 96-well plates (5×10^3 / well) and cultured for 24 hours. The old culture medium was discarded and replaced with the experimental sample of equal weight. The cells were pretreated for 24 hours, and then hydrogen peroxide with a final concentration of 400 μM was added and incubated for 4 hours. Cell viability was determined by the CCK-8 assay.

[0075] Cell viability (%) = (OD value of test sample / OD value of blank sample) × 100%.

[0076] Table 3. Determination of the antioxidant stress capacity of the compositions. Group DPPH clearance rate (%) Cell survival rate (%) after hydrogen peroxide damage Composition 1 89.2 86.5 Composition 2 82.4 70.1 Composition 3 85.3 82.9 Composition 4 76.9 75.4 Composition 5 79.2 78.1 Composition ① 65.8 63.9 Composition ② 53.1 61.5 Composition ③ 60.5 69.1 Composition ④ 57.4 66.2 Composition ⑤ 61.6 70.3 Composition ⑥ 59.8 68.6 Composition ⑦ 71.5 65.8 Composition ⑧ 68.9 67.5 Composition 9 48.9 57.5 Composition ⑩ 54.3 62.8 Composition A 41.2 35.8 Composition B 54.7 63.2 Composition C 46.8 55.1 Data analysis indicates that this superior performance relies on the synergistic effect of the complete system. The absence of L-arginine, L-hydroxyproline, L-valine, or yeast polypeptides (compositions ①-④) all lead to a certain degree of decrease in antioxidant capacity, suggesting that certain amino acids may serve as precursors for the synthesis of endogenous antioxidants such as glutathione, and their absence weakens the cell's intrinsic defense reserves. The absence of PDRN from purslane or edelweiss (compositions ⑤ and ⑥) clearly reduces both DPPH scavenging and cell protection rates, indicating that the polyphenols, flavonoids, and other antioxidants abundant in the PDRN from these two plant sources are complementary in scavenging free radicals, together forming a highly efficient first line of direct antioxidant defense. The complete absence of PDRN components (composition ⑧) or the use of non-specific PDRN substitutes (composition ⑨) significantly impairs antioxidant capacity, confirming the unique advantages of specific plant PDRN combinations in terms of antioxidant components. The absence of leukocyte extract (composition 10) also weakened the effect, as the antioxidant enzymes (such as SOD) or anti-inflammatory factors it may provide are crucial for alleviating secondary damage from oxidative stress. The complete lack of amino acid / peptide support (composition 7) resulted in lower cell survival under oxidative attack, highlighting the importance of basal metabolic support in maintaining cellular antioxidant homeostasis. Samples containing only leukocyte extract (composition A) showed limited antioxidant capacity, indicating that its effect is more focused on regulation and repair, requiring synergy with direct antioxidant components. Compositions with altered internal ratios (4, 5, B, C) did not achieve optimal effects, suggesting that specific ratios between components are related to the efficient synergy and balance between different antioxidant mechanisms (direct scavenging, enzymatic defense, and anti-inflammatory repair). Therefore, the compositions of this invention construct a multi-layered, integrated antioxidant defense system: dual plant PDRNs are responsible for directly neutralizing free radicals; amino acids / peptides support the synthesis of endogenous antioxidant systems and maintain cell health; and leukocyte extracts alleviate oxidative damage by regulating the immune microenvironment and providing repair signals. The synergistic effect of these three components achieves comprehensive antioxidant protection from prevention and neutralization to repair.

[0077] Experiment 4: Human Efficacy Test Test samples: serums 1-7, serums ①-⑩, AC, and blank serum.

[0078] Subjects: Healthy volunteers aged 35-55 years; Selection criteria: Facial skin conforms to Fitzpatrick type III-IV; self-assessment indicates dry skin with fine lines; baseline transepidermal water loss (TEWL) ≥15 g·h -1 ·m- 2 Sign an informed consent form.

[0079] Exclusion criteria: Pregnant or breastfeeding women; those with a history of active skin disease; those with lesions at the test site; those who have used potent skin-renewing products such as retinoic acid or glycolic acid within the past month; and those with a history of allergy to any ingredient in the test product.

[0080] Subject grouping: Subjects were randomly divided into groups of 10, with each group corresponding to a different experimental sample.

[0081] Test method: The test was conducted in a constant temperature and humidity chamber (temperature 22±2°C, humidity 50±5%RH), where subjects were required to sit quietly for 30 minutes.

[0082] A fixed test area (2cm×2cm) was marked on both sides of the subject's cheeks.

[0083] After cleansing your face every morning and evening, apply the designated sample (approximately 0.05 mL) evenly to the corresponding test area and gently massage until absorbed.

[0084] Use continuously for 28 days.

[0085] Before use (D0) and on day 28 after use (D28). Each measurement was performed in the same environment and at the same time.

[0086] Test parameters and instruments: Transepidermal water loss (TEWL): Measured using a Tewameter®™ 300 (CK, Germany), in g·h. -1 ·m- 2 The lower the value, the more intact the skin barrier function.

[0087] Stratum corneum moisture content (SCH): Measured using a Corneometer® CM825 (CK, Germany), unit is arbitrary (AU). The higher the value, the better the skin hydration.

[0088] Skin elasticity (R2): Measured using a Cutometer® MPA580 (CK, Germany), employing the suction-stretch principle. The higher the R2 value, the better the skin elasticity.

[0089] Reduction rate (%) = (D0 - D28) / D0 × 100% Improvement rate (%) = (D28 - D0) / D0 × 100% Table 4 Results of Human Function Test Group TEWL reduction rate (%) SCH improvement rate (%) Skin elasticity R2 improvement rate (%) Serum 1 38.5 32.8 28.1 Serum 2 35.2 30.5 26.5 Serum 3 35.3 28.6 24.9 Serum 4 28.3 23.8 20.4 Serum 5 30.8 25.3 22.1 Serum 6 20.1 18.2 15.3 Serum 7 36.9 30.2 26.3 Serum ① 26.5 21.6 19.2 Serum ② 24.8 20.2 17.9 Serum ③ 27.1 22.3 20.2 Essence ④ 25.9 21.1 18.7 Essence ⑤ 28.9 23.9 21.3 Essence ⑥ 27.8 22.8 20.5 Essence ⑦ 22.4 18.6 16.8 Serum ⑧ 25.3 20.2 18.1 Serum 9 22.7 18.9 16.5 Serum 10 25.6 20.3 18.2 Serum A 9.8 15.6 8.5 Serum B 26.3 21.8 19.8 Serum C 21.8 17.5 15.7 Blank Essence 3.5 2.1 1.5 This test case, through a 28-day clinical study, verified the actual repair and anti-aging efficacy of each serum sample on human skin. Serum 1, containing core composition 1, achieved comprehensive and significant best improvement in three key clinical indicators: improving skin barrier function (reducing TEWL), increasing stratum corneum moisture content (increasing SCH), and enhancing skin elasticity (increasing R2 value). The effects of all control serums were lower than those of serum 1 to varying degrees, a trend that is highly consistent with and corroborates the conclusions of in vitro cell experiments (test cases 1-3). Specifically, serums ①-⑩ (corresponding to compositions ①-⑩ lacking one or some components) showed a systematic decline in clinical efficacy, directly proving that each active component is indispensable in achieving the final visible clinical effect. For example, serums ① and ② (lacking key amino acids) were insufficient in moisturizing and improving elasticity, reflecting the dependence of clinical efficacy on the skin's own anabolic metabolism. Serums ⑤ and ⑥ (lacking specific PDRNs) were slightly inferior in barrier repair and overall skin texture improvement, indicating that the two plant PDRNs have different focuses in synergistically resisting environmental damage and promoting healthy skin renewal. The efficacy of serum ⑩ (lacking leukocyte extract) was also clearly limited, confirming its crucial role in the systemic regulation of the skin microenvironment and repair process. Serum ⑦ (completely lacking amino acids / peptides) and serum A (containing only leukocyte extract) had the lowest clinical efficacy, extremely demonstrating that a lack of nutritional foundation or a lack of core repair and regulatory network makes it difficult to achieve effective skin improvement in humans. Serum ⑨, using non-specific PDRNs, also had unsatisfactory effects, highlighting the clinical advantages of compounding with PDRNs from specific plant sources. Serum 6 (0.5%), with varying active ingredient content, showed weaker effects, while serum 7 (5%) and serum 1 (3%) had similar effects, indicating the effective concentration range of the composition. The clinical efficacy of serums B and C, with altered internal formulations, failed to surpass that of serum 1, confirming that the specific mass ratio is key to achieving optimal efficacy in the human body. In summary, our human trial data ultimately demonstrates that the complete system composed of the seven components in a specific mass ratio, through a multi-level, integrated synergistic mechanism of "deep nutrient supply and metabolic support (amino acids / peptides) - mid-layer damage repair, defense and renewal (dual plant PDRN) - global microenvironment regulation and regeneration signal modulation (leukocyte extract)," can achieve outstanding and comprehensive barrier repair, hydration enhancement, anti-wrinkle, and anti-aging effects on human skin.

[0090] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the essence and scope of the technical solutions of the present invention.

Claims

1. A skin care composition with synergistic repair and anti-aging effects, characterized in that, Includes the following components: L-arginine, L-hydroxyproline, L-valine, yeast polypeptide, PDRN from purslane, PDRN from edelweiss, and leukocyte extract; The mass ratio of PDRN derived from purslane to PDRN derived from edelweiss is 1:(0.1-1).

2. The skin care composition according to claim 1, characterized in that, Includes the following components by weight: L-Arginine: 0.1-1.5 parts; L-Hydroxyproline: 1.0-3.0 parts; L-valine: 0.5-1.5 parts; Yeast polypeptides: 1.0-3.0 parts; PDRN from purslane: 1.0-3.0 parts; PDRN from Edelweiss: 0.3-1.5 parts; Leukocyte extract: 0.5-2.0 parts.

3. The skin care composition as described in claim 2, characterized in that, Includes the following components by weight: L-arginine: 1.0 part; L-hydroxyproline: 2.0 parts; L-valine: 1.0 part; Yeast polypeptide: 2.0 parts; PDRN from purslane: 2.0 copies; PDRN from Edelweiss: 1.0 copy; Leukocyte extract: 1.0 part.

4. The use of a skin care composition as described in any one of claims 1-3 in the preparation of a cosmetic for repairing the skin barrier.

5. The use of the skin care composition according to any one of claims 1-3 in the preparation of cosmetics for promoting collagen synthesis, anti-wrinkle, and anti-aging.

6. The application as described in claim 4 or 5, characterized in that, The cosmetics are in the form of serum, lotion, cream, gel, or mask.

7. A serum with repairing and anti-aging effects, characterized in that, The serum comprises the skin care composition as described in any one of claims 1-3.

8. The essence as described in claim 7, characterized in that, The serum also includes excipients acceptable in the cosmetics field, which are selected from one or more of moisturizers, emulsifiers, thickeners, preservatives, pH adjusters, and solvents.

9. The essence as described in claim 7, characterized in that, The moisturizer is one or more of glycerin, sodium hyaluronate, and 1,3-butanediol.

10. The essence as described in claim 7, characterized in that, The solvent is deionized water and / or oil.